This phase II study (NCT03635892) tested the administration of nivolumab and cabozantinib in treatment-naïve, or previously treated with one VEGF-R TKI or mTOR inhibitor, patients with pRCC, MiT family translocation RCC, unclassified RCC (cohort 1), or chRCC (cohort 2). This evidence concerns the gene KDR and chromophobe renal cell carcinoma.